Loading clinical trials...

Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy | Clinical Trials | Clareo Health

COMPLETED

Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy

Study Aiming to Measure the Impact on Immune Activation and Inflammatory Markers of Switching From a Triple Combination Antiretroviral Therapy (cART) to a Long Acting Dual Therapy in HIV-infected Patients

NCT05433987•Centre Hospitalier de Cannes Simone Veil

View on ClinicalTrials.gov

Summary

The purpose of the study is to measure the impact on immune activation and inflammatory markers of switching from a triple combination antiretroviral therapy (cART) to a long acting dual therapy in HIV-infected patients

Detailed Description

Patients meeting the inclusion criteria will be offered to participate to the study. In case of acceptance by given their writting consent, 6 ml of blood will be collected for measuring immune activation and inflammatory markers, during the blood test scheduled for the routine follow-up. Six months after cART change, an equal volume of blood will be collected for measuring the same immune activation and inflammatory markers

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients agreeing to participate to the study and to collect their data
•HIV-1 infected subjects
•Patients switching from a stable (at least 6 months) and successful triple cART to a long acting dual cART
•Patients older than 18 yrs and regularly followed in Cannes and Nice hospitals
•Patients with a healthcare card

Exclusion Criteria

•HIV-2 infected subjects
•Patients not being on successful and stable cART
•Patients having being treated during acute HIV-infection
•Patients modifying cART for virological failure
•Subjects modifying their treatment for another combination than from a triple cART to a dual cART
•Patients modifying cART during the 6 months of follow-up
•Patients refusing to participate to the study
•Patients included in an interventional study during the 6 months of follwo-up
•Patient under juridical procedure

Locations (1)

Nathalie DOUX

Cannes, France

Key Dates

Start Date

July 28, 2022

Primary Completion Date

November 17, 2023

Completion Date

November 17, 2023

Last Updated

August 28, 2024

Enrollment

ACTUAL participants

Conditions

HIV-1-infection

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV

NCT07055451

HIV-1-infection

View study

RECRUITINGNA

Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)

NCT05136703

DepressionHIV-1-infection+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 28, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy

Inclusion Criteria

Exclusion Criteria

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV

Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)

Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

Caspofungin for Pneumocystis Pneumonia in PLWHIV.

PrEPsmart 2-1-1 Pilot